logo-loader
viewArix Bioscience PLC

Arix Biosciences portfolio company Aura encouraged by trial results of eye cancer treatment

Tumour control and vision preservation data continue to be supportive of the planned Phase 3 registration trial in the second half of 2020

Arix Bioscience PLC -
Arix has a portfolio of sixteen investee companies that have numerous treatments currently going through clinical trials

Arix Bioscience PLC (LON:ARIX) portfolio company Aura Biosciences has presented updated clinical data from its ongoing Phase 1b/2 clinical trial of its first-line treatment for a rare but potentially fatal form of eye cancer.

The data was presented to the 43rd Annual Macula Society meeting in San Diego and demonstrated multiple administrations of light-activated AU-011 were well-tolerated in patients suffering from primary choroidal melanoma.

Tumour control and vision preservation data continue to be supportive of the planned Phase 3 registration trial in the second half of 2020, the statement added.

Cadmus Rich, Aura’s chief medical officer and head of research and development, said: “The high tumour control rates observed to date, together with the high rate of vision preservation, including in patients at high risk for vision loss with sub-macular and peripapillary tumours continue to support AU-011’s significant potential to change the treatment paradigm for patients battling choroidal melanoma.”

A biotech investment company, Arix has a portfolio of sixteen investee companies that have numerous treatments currently going through clinical trials.

Quick facts: Arix Bioscience PLC

Price: 85 GBX

LSE:ARIX
Market: LSE
Market Cap: £115.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience associate talks through current promising coronavirus...

Arix Bioscience PLC (LON:ARIX) Investment Associate Tim Xu tells Proactive what he believes are promising therapeutics currently being innovated by a variety of biotechs around the word. Xu, who recently published a blog post entitled "How close are we to a COVID-19 cure? A biotech VC...

on 21/4/20

2 min read